For almost two hundred years, diabetes mellitus has been a major health problem worldwide. While there has been progress in our knowledge of its pathophysiology and treatment, the therapeutic choices available today are woefully inadequate. The goal of transdermal medication delivery systems is to provide therapeutically effective doses of a medicine via the skin. The medicine is released at a steady, regulated pace thanks to the design of these devices. As a result, it is well suited for the management of long-term conditions like diabetes. Thus, the risks and inconvenient nature of the oral and parenteral routes are avoided. The purpose of this study is to develop and test eucalyptol transdermal patches for the treatment of diabetes. Drug distribution from different polymer-based transdermal patches might be enhanced by using oleic acid as a penetration enhancer. Matrix-style transdermal patches, composed of PVP K30, HPMC K100, and solvent, were created utilizing solvent casting procedures. By using Fourier transform infrared spectroscopy, researchers were able to examine the drug's and polymers' physicochemical compatibility. No evidence of physical or chemical incompatibility between the medication and the polymers was found. The patches also underwent a battery of physical tests in addition to the in-vivo research. The patches with the polymers, that is, PVP K30, HPMC K100, and oleic acid as the penetration enhancer, were regarded the best formulations for the transdermal distribution of eucalyptol based on the findings obtained from the physical assessment, ex vivo investigations, and in-vivo studies.
The current research aims to formulate and evaluated Cinnamaldehyde transdermal patches to treat diabetes. A good penetration enhancer Oleic Acid, would improve drug delivery from various polymer-based transdermal patches. Transdermal patches of the matrix type were made by solvent casting techniques using various polymer PVP K30, HPMC K100, and solvent. All prepared formulations were tested for folding endurance, weight variation, thickness, drug content, moisture content, moisture loss, in vitro drug release and In- vivo studies. Batch TDP1 was optimised formula from all formulation batches shows zero order release for 24 hours, with a cumulative percentage of drug diffusion of 97.68% from 2cm2 patches. It has been determined that polymer concentration HPMC films showed better release which may be attributed to the reason of high water vapour permeability of HPMC films for enhancing diffusion rate of drug through rat skin, oleic acid were incorporated as permeation enhancers in the HPMC films since they showed better release. It allows for controlled drug release from the patch. Drug content of the patches was found to be more than 98%. Variations in flux and Diffusion Coefficient were observed among various formulations. The drug–polymer interaction results suggested no interaction between drug and polymers. The in vivo results revealed that the patches successfully prevented the hyperglycaemia and they were also effective on chronic application. The transdermal route exhibited negligible skin irritation and produced better improvement with all the tested in vivo parameters compared to oral administration.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.